AMACR and lung neuroendocrine neoplasm: Shilo et al. reported overexpression of AMACR in pulmonary neuroendocrine tumours, with AMACR expression in 72 % (31 of 43) of typical carcinoids, 52 % (15 of 29) of atypical carcinoids, 70 % (16 of 23) of large cell neuroendocrine carcinomas and 51 % (32 of 63) of small cell carcinomas [22].